Work

Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer.

Year: 2015

Type: review

Abstract: To discuss the mechanism and clinical application of EGFR-TKI and ALK/ROS1 inhibitors in non-small cell lung cancer (NSCLC), we reviewed recent available data mainly from PubMed. We found that chemotherapy, progression-free survival (PFS), objective response rate (ORR), and quality of life of patients with advanced NSCLC can be greatly improved in these drugs medication compared with conventional chemotherapy. Though many questions like resistance to EGFR-TKI and ALK/ROS1 inhibitors exist, molecular targeted therapy is an important therapeutic method for the management of NSCLC. The role of molecule targeted therapy in the initiation and development of NSCLC deserves further study.

Source: PubMed

Authors: Liangqing Ge, Ruizheng Shi

Institutions: Central South University, The First People's Hospital of Changde, Xiangya Hospital Central South University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W2404215831

FWCI: 0.819

Cites: 65

Cited by: 22

Related to: 10